HER2+ Metastatic Breast Cancer: Factors in Selecting Optimal Therapy

December 16, 2022

By Sarah M. Tolaney, MD, MPH
Nancy U. Lin, MD

Video

Having outlined available treatment options for patients with HER2+ metastatic breast cancer, expert panelists share which factors help to select optimal therapy.

EP: 1.Patient Case 1: Patient With HER2+ Metastatic Breast Cancer and no CNS Disease

EP: 2.Treatment Armamentarium for HER2+ Metastatic Breast Cancer

Now Viewing

EP: 3.HER2+ Metastatic Breast Cancer: Factors in Selecting Optimal Therapy

EP: 4.Strategies to Identify and Delay Brain Metastases in HER2+ Breast Cancer

EP: 5.Patient Case 2: HER2+ Breast Cancer With CNS Metastases

EP: 6.Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease

EP: 7.HER2+ Metastatic Breast Cancer: Role of Radiation Therapy in Managing CNS Disease

EP: 8.HER2CLIMB: Role of Tucatinib in Treating HER2+ mBC With CNS Disease

EP: 9.HER2+ mBC With CNS Disease: Sequencing Therapy After Progression on Tucatinib

EP: 10.Novel Combination Strategies in HER2+ Metastatic Breast Cancer With CNS Disease

EP: 11.Patient Case 3: HER2+ Metastatic Breast Cancer With CNS Disease

EP: 12.HER2+ Metastatic Breast Cancer: Guidance on MRI Use After CNS Radiation

EP: 13.Optimizing Care of Patients on T-DXd for HER2+ mBC With CNS Disease

EP: 14.Agents in Development for HER2+ Breast Cancer

EP: 15.Managing HER2+ Breast Cancer With Leptomeningeal Metastases

EP: 16.HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

EP: 17.Recap: Treating Patients With HER2+ Metastatic Breast Cancer: Insights From Experts at Dana- Farber Cancer Institute

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!